STCube Inc
KOSDAQ:052020
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5 580
9 790
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
STCube Inc
STCube, Inc. engages in the development and distribution of information technology (IT) services. The company is headquartered in Seoul, Seoul. The company went IPO on 2001-07-05. Along with subsidiaries, the Company operates its business through two segments. The Information Technology (IT) segment is engaged in the distribution of closed-circuit television (CCTV) lenses and related components. The Biotechnology (BT) segment is engaged in the development and licensing of immunomodulatory anticancer drug therapeutic candidates.
STCube, Inc. engages in the development and distribution of information technology (IT) services. The company is headquartered in Seoul, Seoul. The company went IPO on 2001-07-05. Along with subsidiaries, the Company operates its business through two segments. The Information Technology (IT) segment is engaged in the distribution of closed-circuit television (CCTV) lenses and related components. The Biotechnology (BT) segment is engaged in the development and licensing of immunomodulatory anticancer drug therapeutic candidates.
